<DOC>
	<DOCNO>NCT03063541</DOCNO>
	<brief_summary>Purpose study ass hypothesis strategy acetylsalicylic acid ( ASA ) 100 mg/day , intensive blood pressure treatment ( target systolic blood pressure 120 mmHg ) , blood pressure measure device reduces risk aneurysm rupture growth compare standard care ( i.e . ASA , blood pressure management accord standard blood pressure management , blood pressure measure device )</brief_summary>
	<brief_title>Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment Patients With Unruptured Intracranial Aneurysms</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients 18 year old intradural , saccular unruptured aneurysm ( UIA ) decide intervene preventive endovascular neurosurgical repair aneurysm monitor regular base aneurysm growth Last aneurysm image either CTA/MRA/DSA within last 3 month All nonsaccular UIAs aneurysm relate arteriovenous malformation Frequent ASA use and/or indication vitamin K antagonist , direct oral anticoagulant ( DOAC ) treatment baseline Contraindication ASA History hypersensitivity ASA drug similar chemical structure excipient present pharmaceutical form ASA Chronic kidney disease stage IV V ( GFR &lt; 30 mL/min/1.73 m2 ) Pregnancy lactation Participation another clinical trial observation period compete trial , respectively Lifeexpectancy &lt; 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>